For instance, a recent phase 2 study investigated the efficacy of regorafenib, a potent inhibitor of angiogenic and oncogenic kinases, in combination with the PD-1 inhibitor camrelizumab and chemotherapy in patients with treatment-naïve advanced GC, which revealed a favorable objective response rate of 61.5% in the CPS<1 subgroup (Peng et al., 2021). The gene discussed is PDCD1; the disease is gastric cancer.